handGismo Therapeutics Inc. is a biotech start-up company targeting fundamental biochemical processes that are at the root of Alzheimer’s and Parkinson’s Disease pathogenesis. The company has been awarded in quick succession several prestigious research grants during 2013-2014 to further develop its industry-leading technology, GISMO, which is associated with a new hypothesis of the etiology of major neurodegenerative diseases. Gismo Therapeutics Inc. is developing first-in-class oral therapeutics for the treatment of both Alzheimer’s Disease and Parkinson’s Disease.